EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program

Marla C Dubinsky, Alessandro Armuzzi, Krisztina B Gecse, Thomas Ullman, Andrew G Bushmakin, Marco DiBonaventura, Joseph C Cappelleri, Susan B Connelly, John C Woolcott, Leonardo Salese

Digestive Diseases · 2023

DOI: 10.1159/000528788 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Digestive Diseases, 2023. Verfasst von Marla C Dubinsky und 9 weiteren Autor:innen. Beteiligte Einrichtung: Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with ulcerative colitis (UC) often report impaired health-related quality of life (HRQoL). Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of UC. In addition to previous demonstrations of improved clinical measures (e.g., Mayo score), tofacitinib has been shown to improve HRQoL in patients with UC. This analysis explored the interrelationships among tofacitinib treatment, HRQoL, and disease activity (measured using Mayo subscores) using mediation modeling.

Methods

Data were collected from two 8-week induction studies (OCTAVE Induction 1 and 2) in patients with moderate to severe UC treated with tofacitinib or placebo. Two mediation models were specified. First, Mayo subscores were mediators between the binary treatment variable (tofacitinib vs. placebo) and the eight Short Form-36 Health Survey (SF-36) domain scores as outcomes. Second, the four Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores served as outcomes. Both models used data collected at week 8.

Results

Overall, 1,073 and 1,079 patients were included in the SF-36- and IBDQ-based models, respectively. For all SF-36 domains, improvements in Mayo subscores were estimated to explain 65.6% (bodily pain) to 92.9% (mental health) of the total treatment effect on SF-36 domain scores (all p < 0.05). For all IBDQ domains, improvements in Mayo subscores explained 71.6% (systemic symptoms) to 84.7% (emotional function) of the total treatment effect (all p < 0.05).

Conclusion

Mayo scores and Mayo subscores are significant but incomplete contributors to tofacitinib’s effect on HRQoL in patients with moderate to severe UC. ClinicalTrials.gov: NCT01465763; NCT01458951.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansPiperidinesPyrimidinesQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

GastroenterologyHealth-related quality of lifeInflammatory bowel diseasePatient-reported outcomesStatistical modelingUlcerative colitis

Substanzen

PiperidinesPyrimidinestofacitinib

Autor:innen und Institutionen

  • Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • IBD Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Academic Medical Center, Amsterdam, The Netherlands.
  • Division of Gastroenterology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Pfizer Inc, Groton, Connecticut, USA.
  • Pfizer Inc, New York, New York, USA.

Zitieren

APA

Dubinsky, M. C., Armuzzi, A., Gecse, K. B., Ullman, T., Bushmakin, A. G., DiBonaventura, M., Cappelleri, J. C., Connelly, S. B., Woolcott, J. C., & Salese, L. (2023). Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program. Digestive Diseases. https://doi.org/10.1159/000528788

Vancouver

Dubinsky MC, Armuzzi A, Gecse KB, Ullman T, Bushmakin AG, DiBonaventura M, et al. Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program. Digestive Diseases. 2023. doi:10.1159/000528788

BibTeX
@article{Dubinsky2023,
  author = {Dubinsky, Marla C and Armuzzi, Alessandro and Gecse, Krisztina B and Ullman, Thomas and Bushmakin, Andrew G and DiBonaventura, Marco and Cappelleri, Joseph C and Connelly, Susan B and Woolcott, John C and Salese, Leonardo},
  title = {Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program},
  journal = {Digestive Diseases},
  year = {2023},
  doi = {10.1159/000528788}
}
Kostenlos starten →